Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
20,458
Total Claims
$2.8M
Drug Cost
931
Beneficiaries
$3,001
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
-24%
Cost per patient vs peers
$3,001 vs $3,933 avg
-23%
Brand preference vs peers
39.3% vs 51.2% avg
Brand vs Generic
Brand: 7,881 claims · $2.6M
Generic: 12,196 claims · $210K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 458 | $452K |
| Empagliflozin | 375 | $286K |
| Dapagliflozin Propanediol | 392 | $256K |
| Insulin Glargine,hum.Rec.Anlog | 568 | $242K |
| Sitagliptin Phos/Metformin Hcl | 360 | $226K |
| Levothyroxine Sodium | 3,781 | $215K |
| Sitagliptin Phosphate | 242 | $165K |
| Sitagliptin Phos/Metformin Hcl | 142 | $93K |
| Insulin Glargine,hum.Rec.Anlog | 148 | $92K |
| Empagliflozin/Metformin Hcl | 104 | $69K |
| Insulin Lispro | 141 | $67K |
| Empaglifloz/Linaglip/Metformin | 80 | $51K |
| Omega-3 Acid Ethyl Esters | 530 | $39K |
| Dapaglifloz Propaned/Metformin | 61 | $37K |
| Insulin Nph Hum/Reg Insulin Hm | 58 | $36K |
Prescribing Profile
Patient Profile
72
Avg Age
74%
Female
1.61
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data